Research programme: small molecule anticancer therapeutics - Telik

Drug Profile

Research programme: small molecule anticancer therapeutics - Telik

Alternative Names: 8967; EAAF; TLK 60357; TLK 60596

Latest Information Update: 16 Mar 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Telik
  • Class Small molecules
  • Mechanism of Action Microtubule protein modulators; Signal transducing adaptor protein inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 31 Dec 2011 Suspended - Preclinical for Cancer in USA (PO)
  • 30 Jun 2010 This programme is still in active development
  • 16 Apr 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top